- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
E-Z-EM signs deal with Eli Lilly
Contrast agent developer E-Z-EM has signed an agreement with pharmaceutical giant Eli Lilly for U.S. marketing of Lilly’s Glucagon for Injection product, a recombinant form of glucagon. Lilly will pay E-Z-EM a promotional fee based on sales of the
Contrast agent developer E-Z-EM has signed an agreement with pharmaceutical giant Eli Lilly for U.S. marketing of Lillys Glucagon for Injection product, a recombinant form of glucagon. Lilly will pay E-Z-EM a promotional fee based on sales of the injectable product, which is used in diagnostic procedures for the gastrointestinal system and for the treatment of severe hypoglycemia in diabetic patients. When used in gastrointestinal diagnostics, glucagon relaxes smooth muscles in the gastrointestinal tract, and may improve the quality of radiological images. The deal is part of E-Z-EMs strategy of forging healthcare alliances to bring key products to market, according to Howard Stern, chairman of the Wesbury, NY-based E-Z-EM. Lilly launched Glucagon in March.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
